Please login to the form below
Ranbaxy wins FDA approval for Metformin in US
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
India-based Ranbaxy Laboratories' 100 per cent-owned Ohm Laboratories has won FDA approval to manufacture and market Metformin tablets in the US.
Ipca Laboratories, which has a strategic alliance with Ranbaxy, will manufacture the formulation at its facilities in India. Ranbaxy will commercialise the product in the US market, Ipca revealed in a press statement to the Bombay Stock Exchange.
Total annual US sales for Metformin, an insulin sensitising agent, was USD 379m, according to Ranbaxy.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
No results were found
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
- The other side of … blood cancer
- To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
- COVID-19 – a catalyst for technology adoption in clinical trials
- As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Quick links
Infographics
